However, biodistribution studies using FITC-conjugated TP5 have provided valuable insights, demonstrating that despite its brief circulation time, TP5 can reach various tissues, including lymphoid organs and tumor sites, and, remarkably, can cross the blood–brain barrier to accumulate in brain tissue, with therapeutic efficacy validated in preclinical glioblastoma models [36]. Here, TMPO is linked to neoplasm.